{"DataElement":{"publicId":"7697864","version":"1","preferredName":"Leukodystrophy Therapeutic Procedure Administered Specify Text","preferredDefinition":"The free-text field to describe the leukodystrophy therapy administered.","longName":"7697862v1.0:2799057v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7697862","version":"1","preferredName":"Leukodystrophy Therapeutic Procedure Administered","preferredDefinition":"A group of rare genetic neurodegenerative disorders that affect infants and children. These disorders are characterized by metabolic abnormalities in the development of the myelin sheaths in the white matter. Clinical signs and symptoms include developmental delays, mental retardation, dementia, seizures, loss of motor skills, and muscle weakness. Representative examples include metachromatic leukodystrophy, Krabbe disease, Canavan disease, and Alexander disease._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).","longName":"7697860v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7697860","version":"1","preferredName":"Leukodystrophy Therapeutic Procedure","preferredDefinition":"A group of rare genetic neurodegenerative disorders that affect infants and children. These disorders are characterized by metabolic abnormalities in the development of the myelin sheaths in the white matter. Clinical signs and symptoms include developmental delays, mental retardation, dementia, seizures, loss of motor skills, and muscle weakness. Representative examples include metachromatic leukodystrophy, Krabbe disease, Canavan disease, and Alexander disease.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C61253:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukodystrophy","conceptCode":"C61253","definition":"A group of rare genetic neurodegenerative disorders that affect infants and children. These disorders are characterized by metabolic abnormalities in the development of the myelin sheaths in the white matter. Clinical signs and symptoms include developmental delays, mental retardation, dementia, seizures, loss of motor skills, and muscle weakness. Representative examples include metachromatic leukodystrophy, Krabbe disease, Canavan disease, and Alexander disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C54CDA77-189A-1C9F-E053-4EBD850A19BC","latestVersionIndicator":"Yes","beginDate":"2021-06-21","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-06-21","modifiedBy":"ONEDATA","dateModified":"2021-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C54CDA77-18A8-1C9F-E053-4EBD850A19BC","latestVersionIndicator":"Yes","beginDate":"2021-06-21","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-06-21","modifiedBy":"MALUMK","dateModified":"2021-11-01","changeDescription":"Released. 11/01/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2799057","version":"1","preferredName":"Specify Text","preferredDefinition":"Be specific about something; define clearly._Text; the words of something written.","longName":"SPC_TXT","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2799056","version":"1","preferredName":"Specify Text","preferredDefinition":"Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D89B-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"ONEDATA","dateModified":"2008-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D8AC-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"MALUMK","dateModified":"2021-01-19","changeDescription":"03/17/10-Added CSI for F2000-CJL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify the leukodystrophy th","type":"Preferred Question Text","description":"Specify the leukodystrophy therapy administered:","url":null,"context":"NHLBI"},{"name":"Specify other therapy:","type":"Application Standard Question Text","description":"Specify other therapy:","url":null,"context":"NHLBI"},{"name":"Specify other therapy:","type":"Alternate Question Text","description":"Specify other therapy:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C54CDA77-18FD-1C9F-E053-4EBD850A19BC","latestVersionIndicator":"Yes","beginDate":"2021-06-21","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-06-21","modifiedBy":"MALUMK","dateModified":"2021-11-01","changeDescription":"Released. 11/01/2021 KMM; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}